For the second time, BioSciCon, Inc. and Dr. Olivera Markovic were announced winners for the Corporate Vision Magazine Business Woman Awards (2017)
Awards and Recognitions
Dr. Olivera Markovic was nominated to receive Business Woman of the Year Award 2017 Dr. Olivera Markovic has been selected for 2017 Marquis Lifetime Achievement Award BioSciCon, Inc. has been selected for the 2017 Best of Rockville Award for Biotechnology Research by the Rockville Business Recognition Award Program April 2017 Drs. Olivera and Nenad Markovic contributed to the Experimental Biology National Meeting, EB Chicago, 2017 with a report on Cervical Cancer and HPV: Dilemmas and Resolution via Biomarkers. See Reference #60. January 2017
Dr. Olivera Markovic was nominated to receive Business Woman of the Year Award 2017
Dr. Olivera Markovic has been selected for 2017 Marquis Lifetime Achievement Award
BioSciCon, Inc. has been selected for the 2017 Best of Rockville Award for Biotechnology Research by the Rockville Business Recognition Award Program
Drs. Olivera and Nenad Markovic contributed to the Experimental Biology National Meeting, EB Chicago, 2017 with a report on Cervical Cancer and HPV: Dilemmas and Resolution via Biomarkers. See Reference #60.
2016 Awards and Recognitions for BioSciCon, Inc.
Labroots Virtual Meetings
It is to announce that Dr. Olivera Markovic is elected Adjunct Professor of Biological Sciences at the University of Maryland Baltimore County. She is currently teaching classes in Graduate Master Degree Program in Biotechnology at UMBC, USG. This is the fifth professorship granted to Dr. Markovic, after Medical Faculty, University in Belgrade, former Yugoslavia, Medical College of Pennsylvania/Drexel University in Philadelphia, PA, Georgetown University, in Washington, DC and American University in Washington DC.
A new composite marker for cervical dysplasia
MEDYKO is a new upgraded MarkPap® biomarker. It is an acronym of ME (metabolic biomarker--acid phosphatase), DY (pathocytological signs of dysplasia) and KO (koilocyte sign of HPV disease). MOTHER'S DAY 2016 Message from the President Mothers of the World, Foundation of the Family and its Guiding Force, our Heroes -- Happy Mother’s Day! November 2015 BioSciCon Introduces the New Proprietary Biomarker BioSciCon, Inc. and the Global Academy for Women's Health have submitted an abstract for the 2016 Experimental Biology Annual Meeting in San Diego, CA , where intend to present their new proprietary biomarker for cancer diagnosis via global mobile telecytopathology. BioSciCon, Inc. has been selected for 2015 American Leadership Award by the American Economic Institute, Washington, DC. August 2015 BioSciCon, Inc. receives 2015 Best of Business Award for Rockville Small Business Community Association recently selected BioSciCon, Inc. to receive 2015 Best of Business Award for Rockville, MD in the Small Business category. July 2015 BioSciCon's MarkPap® [CAP-PAP™] Test in India We have a long-standing collaboration with Indian scientists where the validity of the of the MarkPap test (CAP-PAP test) in detection of abnormal cells on cervical smears has been confirmed. Please see Publications 38, 51. In the beginning of this year two more scientific papers were published on the subject in India. Our book "What every woman should know about cervical cancer'( Springer, 2008) is popular in India. Recently, two Indian distributors joined the list: Delhi Book Store and Meltek Books. June 2015 BioSciCon's MarkPap® Images in China Original, copyrighted image of a specimen processed with MarkPap® Test, presented on BioSciCon's Gallery page, are plagiarized and published without permission at the website of the Chinese Anhui Science and Technology Co.
MEDYKO is a new upgraded MarkPap® biomarker. It is an acronym of ME (metabolic biomarker--acid phosphatase), DY (pathocytological signs of dysplasia) and KO (koilocyte sign of HPV disease).
MOTHER'S DAY 2016
Message from the President
Mothers of the World, Foundation of the Family and its Guiding Force, our Heroes -- Happy Mother’s Day!
BioSciCon Introduces the New Proprietary Biomarker
BioSciCon, Inc. and the Global Academy for Women's Health have submitted an abstract for the 2016 Experimental Biology Annual Meeting in San Diego, CA , where intend to present their new proprietary biomarker for cancer diagnosis via global mobile telecytopathology.
BioSciCon, Inc. has been selected for 2015 American Leadership Award by the American Economic Institute, Washington, DC.
BioSciCon, Inc. receives 2015 Best of Business Award for Rockville
Small Business Community Association recently selected BioSciCon, Inc. to receive 2015 Best of Business Award for Rockville, MD in the Small Business category.
BioSciCon's MarkPap® [CAP-PAP™] Test in India
We have a long-standing collaboration with Indian scientists where the validity of the of the MarkPap test (CAP-PAP test) in detection of abnormal cells on cervical smears has been confirmed. Please see Publications 38, 51.
In the beginning of this year two more scientific papers were published on the subject in India.
Our book "What every woman should know about cervical cancer'( Springer, 2008) is popular in India. Recently, two Indian distributors joined the list: Delhi Book Store and Meltek Books.
BioSciCon's MarkPap® Images in China
Original, copyrighted image of a specimen processed with MarkPap® Test, presented on BioSciCon's Gallery page, are plagiarized and published without permission at the website of the Chinese Anhui Science and Technology Co.
MarkPap® in P.R. China
CAP PAP Test, USPTO #6,143,512 (issued in year 2000), MarkPap®, BioSciCon, Inc, USA is gaining popularity in China. It is sold under different names: NewMark-PAP, NM-PAP from Anhui Science and Technology Co., Ltd and FSC-811 from Anyon Biopharmaceuticals, Ltd, both from Hefei, Anhui Province, PR China.
Citation from www.ahnmst.com
BioSciCon is now offering two MarkPap(r) Technology related new products for licensing/sale. Both are in patent pending phase.
BioSciCon, Inc. and its principals have been recognized, endorsed and selected as award recipient by business organizations, associations, media, bibliographical collections, etc. BioSciCon, acknowledges these awards and is honored by the recognitions.
The participation of BioSciCon and the Global Academy for Women's Health on the January 2014 National Conference on Cancer Detection, Diagnosis and Treatment Technologies for Global Health, appeared in Hopkins News, March 2014.
MarkPap India, LLC, a member of the BioSciCon Consortium, continued with implementation of the Strategy for Fighting Cervical Cancer in India, with simplified, affordable, telemedicine-empowered MarkPap® technology that can bring cervical cancer prevention in rural India, at the BoP, where it is most needed. Unfortunately, at present - in the 21st century - more than 70,000 women a year die in India from preventable cervical cancer.
Global Academy for Women’s Health and BioSciCon participated in the 2014 NIH organized National Conference on Cancer Detection, Diagnosis and Treatment Technologies for Global Health in Bethesda, MD.
Due to popular demand, BioSciCon has upgraded the Consulting Page. Please visit www.bioscicon.com/consulting.html.
Pap Smear Test Can Be Made Available and Accessible to Women World-Wide.
We were present at the 18th International Congress of Cytology in Paris, where the paper entitled "Evaluation of Cytology Screening Strategies for Cervical Cancer In Resource Poor Setting" was presented. Please see the Reference # 51.
BioSciCon, Inc. supported by the Global Academy for Women's Health is currently developing low-cost, simple devices for early detection of oral cancer. Oral cancer is common cancer and is among major health problems in the developing countries, particularly in India. To read more about this most recent effort, click on this link.
BioSciCon, Inc. and its affiliates is continuing its effort for the development of low-cost, simple medical devices which are infrastructure independent and accessible in low-resource countries. Telemedicine (wired and wireless) provides powerful tools to achieve success. Please click here to read "IT Telehealth Center for Telecytopathology" that appeared in The FASEB Journal 2013, 27:874.20.
The Global Academy for Women's Health has submitted Application to the US Indo Government funding for organizing the Symposium "Strategy for Reversing the Negative Trends of Increasing Prevalence and Mortality of Indian Women from Cervical Cancer." The Symposium is anticipated to be held in 2013 at the Johns Hopkins University, Montgomery County Campus in Rockville, MD. The Proposal for a comprehensive strategy to increase the outreach for preventive screening to 50% during the next 10-12 years is in preparation. It is expected that the negative trends of an increasing morbidity and mortality at the current outreach of 6% will start to decrease when reaching 50% point.
In response to the WHO launched the Non-Communicable Disease Action Plan, BioSciCon's Consortium has concentrated on three topics, which are in our domain:
According to the World Health Organization, carcinoma of oral cavity is the sixth most frequent cancer among males in developing countries. Although it represents 2-4% of the malignancies in the western countries, it is estimated to be as high as up to 40% of male cancers in some areas of India.
MarkPap India, LLC Brochure on the "Fighting Cervical Cancer in India"
The Global Academy for Women's Health is strongly supporting the development of low-cost, simple medical diagnostic devices that could be used globally to alleviate the disparity in women's healthcare. Wireless health is providing a wide avenue to advance in this field, since 80% of the world's population lives in regions with mobile phone accessibility.
BioScicon and The Global Academy for Women's Health contributed to FASEB Experimental Biology Annual Meeting, 2012 with the following communications:
The preparation of the Second updated and extended edition of “What Every Woman Should Know about Cervical Cancer" is announced in Hopkins News, February 2012.
The renown international publisher Springer invited Dr. Nenad Markovic and Dr. Olivera Markovic to prepare the second, extended and updated edition of their book “What Every Woman Should know about Cervical Cancer." The first edition was published by Springer in 2008; it is well accepted and is distributed worldwide by Springer, Amazon, and affilited distributors.
BioSciCon, Inc. participated at the 2011 NIH Annual SBIR/STTR Conference, held in June 2011 in Bethesda, MD, with the poster entitled: Capitalization of investing into medical device development on the health market.
Dr. Olivera Markovic, Director of BioSciCon, Inc. provided an interview to the Virginia Telehealth Network on the current progress of telemedicine efforts of BioSciCon's Consortium to bring expert medical healthcare to the remote point-of-care locations in low-resource areas, where it is most needed.
BioSciCon Consortium submitted Application for NIH US India Collaborative Program on Low-Cost Medical Devices.
BioSciCon Consortium submitted Application to NIH for SBIR phase-1 Grant.
BioSciCon, Inc. has been selected for the 2010 Best of Rockville Award in the Biological Research category by the US Commerce Association. Click here to read more.
BioSciCon, Inc. is featured at Virginia Telehealth Network Web Site. BioSciCon, Inc is developing IT and Mobile Telehealth Center for Telecytopathology Services in Rockville, MD
MarkPap Pacific, LLC is featured in Washington Post
MarkPap Pacific, LLC signs a Trade Agreement with Chinese Partner
BioSciCon and its companies on the forefront of mHealth current development
BioSciCon’s Consortium of Companies is on the forefront of mHealth current development. We are developing a platform technology for wireless telecytopathology/telemicroscopy that uses mobile cellphone cameras for capturing microscopic images directly from the microscope in remote locations and wireless transmission of those images to distant centers for evaluation by professionals with or without interceptions of web-based digital-image networking systems. The system provides opportunity for the results to be returned to the end users within hours. We have a patentable discovery that could be a revolutionary solution for improving health service delivery and surveillance in the developing world where it is most needed.
The MarkPap® Wireless Telecytopathology™ is based on our prior experience with our proprietary MarkPap® Digital Telecytopathology™. Application of mobile phones for capturing and transmitting microscopic images directly from the microscope with cellphone camera is not an easy task, but we are aware of the challenges and the Wireless Telecytopathology Team is solving them. Please visit www.bioscicon.com/gallery.html to see the Gallery, the actual images obtained with a cellphone camera, applied for early detection of abnormal cells on cervical smears. The previous Gallery, the MarkPap Gallery, is created with a digital camera and it is possible to compare the quality of images between the two.
mHealth heralds a new era in medical communications and health service delivery and requires capable and well equipped multidisciplinary groups and teams devoting their energy to this task. Then the success is warranted.
BioSciCon, Inc. becomes a Corporate Partner of Johns Hopkins University
BioSciCon's MarkPap® Wireless™ Images for Telehealth
Attention! MarkPap® Wireless™: Wireless telemedicine for pathology and cytopathology
BioSciCon Team for Telecytopathology participated at BIO 2008 International Convention. San Diego, California, June 2008 with a poster in the Innovative Corridor. The title of the presentation is A tool for integration of cytology, HPV screening and telecytopathology.
An independent study using MarkPap test in cervical cancer screening has been performed in India by the Department of Pathology and the Department of Obstetrics and Gynecology of the All India Institute for Medical Sciences (AIMS), New Delhi, India The paper is entitled Cervical acid phosphatase detection: A guide to abnormal cells in cytology smear screening for cervical cancer. It is published in Indian Journal of Cytology, 25 (1),1-5, 2008.
The Global Academy for Women's Health Team participated with an abstract entitled Ask for women' opinion first on FASEB Experimental Biology, 2008. Today's Research: Tomorrow's Health. San Diego, California, April 5-9, 2008.
Drs Markovic participated on the 55th Annual Meeting of the American Society of Cytopathology held in Huston on November 2-6, 2007. They presented the results of the application of MarkPap technology and its prospective in telecytopathology.
Please click here to download the abstract. (PDF format)
BioSciCon participated with a poster MarkPap Test and HPV vaccination in the Innovation Corridor at the BIO 2007 International Convention held in Boston, MA May 6-9, 2007.
At the Larta Venture Forum 2007, BioSciCon had a business Power Point Presentation "BioSciCon presents MarkPap Technology" given by Mr.Michael Dailey. The Forum that was held on May 1 and 2, 2007 in San Francisco, CA, is a cumulative event of the NIH Commercialization Assistant Program, where the new achievements and prospective of MarkPap technology and BioSciCon national and global business opportunities for investment were presented.
BioSciCon participated at the Experimental Biology Meeting held in Washington DC, April 18 -May 2, 2007.
During the course of the NIH Commercialization Assistance Program 2006/2007, BioSciCon presented its business opportunity at the Larta NIH-CAP Outcome Workshop, March 26-30 in Washington, DC.
Dr. Olivera Markovic, Founder of BioSciCon was honored among entrepreneurs 2007 on the Women in Bio 5th Annual Dinner, "Innovation Without Borders" that was held in Washington DC on March 27, 2007.
Local, national and international citations for BioSciCon:
BioSciCon listed as a corporate partner in World Science
Dr. Nenad Markovic presented a poster entitled MarkPap(r) technology, a new business opportunity for the Mid-Atlantic biotechnology in the Innovation Corridor at the Mid-Atlantic 2006 BIO in Washington DC.
BioSciCon, as NIH/SBIR phase 2 grant recipient, was selected by the National Institutes of Health, Bethesda, MD to participate in 2006 NIH Commercialization Assistance Program, to foster commercialization of the MarkPap technology. Larta Institute from Los Angeles, CA was assigned to this program.
Drs. Markovic participated at the Annual Meeting of the American Association for Cancer Research (AACR). They presented the biomarker-based MarkPap Digital technology, which allows the MarkPap test to be performed in a small laboratory by low-trained technician with easy-to-use MarkPap Kit. Guided by marker-positivity, the technician selects suspicious microscopic fields and transmits the images in diagnostic centers for evaluation by professionals. The results could be returned within hours. The MarkPap Digital opens a prospective for cytological screening around the world.
The same prospective for global cervical cancer control with MarkPap technology was presented at the Innovative Corridor, BIO 2006 Convention in Chicago, IL.
Drs. Markovic participated at the Annual Meeting of the American Federation for Clinical Research (AFCR), Clinical Research 2006, held in Washington, DC. They presented their results on the application of the MarkPap test on HPV positive specimens. Since MarkPap could detect HPV infected cells together with cytological signs of abnormality, it was discussed of exploring this test as a potential method for monitoring the success of the HPV vaccination.
At the Clinical Research 2006, Drs. Markovic also announced the prospective of moving Pap test to be performed in doctor's offices, when the new MarkPap Digital will be developed.
Drs. Markovic actively participated on the NIH/NCI organized 4th Early Detection Network Scientific Conference held in Philadelphia. They presented the principle and the pilot results of MarkPap biomarker-based telecytopathology.
From June through December 2005, BioSciCon started systematic research and development of its second generation product MarkPap® Digital in collaboration with New Hope Pharmaceuticals, Inc., Gaithersburg, MD; GT Vision, Inc., Hagerstown, MD and ComputerCraft, Inc., McLean, VA. Because of the presence of the biomarker (the hallmark of MarkPap technology), which is amenable for digital photography and image analysis, MarkPap test is qualified for telecytopathology. This is our new product MarkPap® Digital, a potential integrated device combining image acquisition, image delivery and image analysis modules. MarkPap® Digital will provide an opportunity the slides to be stained in one location and the images from the microscopic field to be transmitted into a center for evaluation. This practically means that a general laboratory technician (in a remote laboratory or a nurse in a doctor’s office) can stain a specimen using the MarkPap® kit and will look on the specimen under the microscope searching only for “red” cells (marker positive--abnormal cells). Then, he/she will capture images with a digital camera (mounted on the microscope) and will transmit them via Internet to the center with pathologist/cytotechnologist for evaluation. The result may be sent back electronically within hours.
The development of another product MarkPap Self, which allows a woman
to take a specimen in the privacy of her home, is also in progress. Please
BioSciCon’ poster, “MarkPap System. Current status and prospective” was presented at the Annual Meeting of the American Society for Cytopathology in San Diego, CA in November, 2005
BioSciCon web site is cited at and is linked with the World Science
web site: http://world-science.net/home/links.html
Read more about BioSciCon presentation on the Century Club Breakfast
at the Business Alliance George Masson Press Release of June 9, 2005
Dr. Olivera Markovic and Dr. Nenad Markovic participated in the Convention
BIO 2005, held in Philadelphia, PA . They presented a poster in
the Innovative Corridor with co-authors Dr. Shelly Parr and Dr. Vojislav
Zizic. The abstract "MarkPap® technology for cervical cancer
control" can be found at:
On May 18, 2005, BioSciCon, Inc. Rockville, MD, received the prestigious SCORE "Small Business Client of the Year 2005 Award." This award was presented to Dr. Olivera and Dr. Nenad Markovic at the Annual SCORE Luncheon at the Wyndham Hotel in Washington, DC in the presence of SCORE Chapter 1 counselors, highest SBA officials and guests. BioSciCon was awarded in recognition of a highly successful company, and for its achievements in the development of new products for cervical cancer screening and prevention that will improve global healthcare and save women's lives.
BioSciCon is announcing the incorporation of a business development
The mission of MarkPap, LLC is to commercialize the MarkPap® technology products. The LLC is accepting applications for new members and for the management team. If interested, please contact us at firstname.lastname@example.org. More information to follow.
News from BioSciCon Research and Development.
BioSciCon is currently developing the MarkPap® Digital and the MarkPap® Self tests.
MarkPap® Digital is the MarkPap® test combined with IT technology into a system for telecytopathology, based upon the biomarker. MarkPap® Digital is intended for low-resource countries, where a general technician can locally perform the simple MarkPap® test with the easy-to-use kit, make digital images of "marked" microscopic fields, and transmit them via internet for evaluation. This is a chance for women in remote parts of the world to have an affordable cervical cancer screening within hours.
MarkPap® Self is also based on the same competitive advantage: The presence of the biomarker on abnormal cells. Since the biomarker is a chemical compound deposited inside the cytoplasm, it is not a subject of deterioration like cellular integrity/morphology. We have seen retained red biomarker even in parts of cytoplasm after cell disintegration. This is a basis of prospective use of MarkPap® test in vaginal specimens of self-obtained material (MarkPap® Self Test). This test could be particularly important for women who do not have access to doctor‚s offices, yet to have cervical cancer screening.
We believe that MarkPap® technology should revive the cytological approach to cervical cancer screening and will provide to the rest of the world the same benefit that Pap test has given to the developed countries. MarkPap® technology is compatible with other technologies for cervical cancer screening.
We have recently completed three clinical trials. We compared a combination (marker+Pap) versus Pap alone, and found that the combination is superior for detection of true positive/abnormal specimens (up to 50%), for reduction of false-negatives (more than 50%), and has equivalent specificity with the control Pap test. The presence of the biomarker reduced the screening time from 6 min to 3 min per slide. A total of 2,000 subject/specimens were analyzed by subgroups including: low- risk general population, high-risk population, Pap smear control for MarkPap® smears, and ThinPrep Pap test control for liquid-based MarkPap® test.
We are proud to announce the development of two new Research Sites in Los Angeles, CA, US. BioSciCon is also developing two new International Research Sites in New Delhi, India and in Belgrade, Serbia and Montenegro. More information will follow.
BioSciCon started exploring equity investment options with local angels and VCs in order to secure financing for the regulatory study required from FDA approval for the US market, and the commercialization of the technology. For more information please contact us at email@example.com, or call 1-301-610-9130.
BioSciCon is finalizing phase II/III clinical laboratory trials of the MarkPap® Test. We are currently searching for funding partnership (with individuals or other enterprises) that will assist us in bringing the new product to market.
A paper by Markovic O, Markovic N, and BioSciCon's Cervical Cancer Study
Group: Cervical acid phosphatase: A biomarker of cervical dysplasia and
potential surrogate endpoint for colposcopy appeared in Disease Markers 19(6), 279-286,
2003/2004. The abstract and the full text are available at:
and STTR Success Story for BioSciCon, Inc.
Markovic N., Markovic, O. Markovic, J. Sundeen, W. Smith Jr., Markovic S., BioSciCon Cervical Cancer Research Group*: Pap test and new biomarker-based technology for enhancing visibility of abnormal cells. 40th American Society for Clinical Oncology Annual Meeting, ASCO 2004, New Orleans, Louisiana. June 2004. J Clin Oncol, 22,9561,2004 www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-003023,00.asp
Drs. Nenad and Olivera Markovic participated in the 3rd Annual Early Detection Research Workshop (EDRN) organized from NCI, NIH in Bethesda, MD. They presented the development of MarkPap® Technology: From idea to commercial products. A biomarker-based, in vitro diagnostic device with potentials for cervical cancer screening. Book of Abstracts P-28, 2004.
Drs. Olivera and Nenad Markovic participated in the 6th Annual SBIR/STTR Conference (June 23-24, 2004), organized by NIH in Bethesda, MD. They presented, as NIH SBIR 2nd phase awardees, their translational research entitled MarkPap® Technology for cervical cancer screening. Abstract Book p.7, 2004.
Dr. Lewis Townsend, President Contemporary Women's Health Associates, Bethesda MD and Drs. Olivera and Nenad Markovic attended the 52nd Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in Philadelphia, PA. They presented the results on MarkPap® test reduces false-negative rates of cervical cancer screening. Townsend L, Markovic O, Markovic N, BioSciCon Cervical Cancer Study Group*, Obstetrics and Gynecology, Suppl. 103, (4), 81S,2004.
*BioSciCon Cervical Cancer Study Group: Parr Shelley, MD., Ross Alan, MD., Sundeen James, MD., Rosser Rufus, MD., Gould Jed MD., Posarac Vladan, MD., Mrs. Linda Townsend.
Dr. James Sundeen, President Diagnostic Pathology Services, Clarksburg, MD and Medical Director Department of Pathology Prince George Hospital, Cheverly, MD attended the American Federation for Medical Research Clinical Research Meeting in Chicago, IL. He presented the results on Cervical Acid Phosphatase and PreservCyt®. Markovic N, Markovic O, Sundeen J, Smith W.Jr: Inv Medicine 52, Suppl 2,80,2004.
Drs. Olivera and Nenad Markovic and Dr. Christopher Kemp, President, Kemp Technologies, Frederick, MD, attended the Experimental Biology Meeting 2004 in Washington, DC. They presented the results on: Could the enzyme-enhanced Pap test be automated? Markovic O, Markovic N, Kemp C: The FACEB J., Experimental Biology 2004, Abstracts Part 1, A200.
Another poster, A cytoplasmic biomarker for liquid-based Pap was presented on the same meeting. Markovic O, Markovic N, Sundeen J., Smith W. Jr: The FACEB J. Experimental Biology 2004, Abstracts Part 1, A200.
Dr. William Smith, Director, Department of Pathology, Suburban Hospital, Bethesda, MD attended the 2004 Biennial Meeting of the American Society for Colposcopy and Cervical Pathology held in Disney's Contemporary Resort, FL, March 2004. He presented the MarkPap® System for cervical cancer screening. Smith W Jr, Markovic N, Markovic O, Kumar A, Bermeyo, Mollish P, late Morris M: ASCCP 2004 Biennial Meeting. Book of Abstracts, p.340.
Dr. Olivera Markovic attended the Symposium on Predictive Oncology & Intervention
Strategies in Nice, France, February 7-10, 2004. She presented the
following scientific communications:
Cervical acid phosphatase: A new biomarker of cervical dysplasia appeared in Arch Oncol 11,243-247,2003. Authors Dr. Olivera Markovic and Dr. Nenad Markovic, with the members of the BioSciCon Cervical Cancer Study Group: Dr. James Sundeen, Dr. William Smith, Dr. Shelley Parr, Dr. Lewis Townsend, Dr. Allan Ross, Dr Rufus Rosser, and Dr. Jed Gould.